B+
Bull case
5%
Probability
Target price
$138.00
Analysis reference price unavailable
Analysis 2026-08-13 · RankAlpha Sentiment Codex
APGE
Apogee TherapeuticsCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexPost-earnings T+3Most likely
B
Base case
88%
Probability
Target price
$135.11
Analysis reference price unavailable
Analysis 2026-08-13 · RankAlpha Sentiment Codex
B-
Bear case
7%
Probability
Target price
$95.00
Analysis reference price unavailable
Analysis 2026-08-13 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-13
Recent news sentiment (30D)
+55.0
Positive
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+61.2
Score
AI commentary
Tone is mixed-to-positive on the pipeline and AbbVie transaction, but the stock is effectively a merger-arbitrage instrument trading near the $135.11 cash consideration. The peer set is loose, with no validated direct operating comparators in the packet. Social coverage, options data, short interest, and employee-score data are unavailable; this is a cautious monitoring setup rather than a fresh bullish re-rating.
RankAlpha Sentiment Codex - 2026-08-13
Open post-earnings memoEvidence flagged
peer set is too generic or lacks enough direct operating comparators
Impact
tentative
Confidence
-
AI events
2026-08-10eventQ2 update confirms APEX progressMedium impact
The August 10 8-K reported positive APEX Part B dose-optimization results, selected the mid-dose regimen for planned Phase 3 initiation, and outlined ELEVATE and ASPIRE expansion plans. The packet does not provide revenue/EPS consensus or a verified earnings surprise. [#SEC-8K-2026-08-10]
2026-09-30eventAbbVie acquisition closingMedium impact
AbbVie agreed to acquire Apogee for $135.11 per share in cash, with closing expected in Q3 2026 subject to shareholder and regulatory approvals. At the $134.55 anchor price, the gross spread is approximately 0.4%. [#SEC-8K-2026-08-10]
2026-11-11catalystMerger-break and transition riskHigh impact
Failure to obtain required approvals could create a large downside gap from the cash offer, while anticipated director resignations add transition risk. The filing states the resignations are not due to disagreement over operations, policies, or practices. [#8-K-2026-08-11]
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-13 • Updated nightlySource: Internal modelMethodology